These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 8218290)

  • 1. Transthyretin mutation Leu-55-Pro significantly alters tetramer stability and increases amyloidogenicity.
    McCutchen SL; Colon W; Kelly JW
    Biochemistry; 1993 Nov; 32(45):12119-27. PubMed ID: 8218290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of lethal and nonlethal transthyretin variants and their relationship to amyloid disease.
    McCutchen SL; Lai Z; Miroy GJ; Kelly JW; Colón W
    Biochemistry; 1995 Oct; 34(41):13527-36. PubMed ID: 7577941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The most pathogenic transthyretin variant, L55P, forms amyloid fibrils under acidic conditions and protofilaments under physiological conditions.
    Lashuel HA; Wurth C; Woo L; Kelly JW
    Biochemistry; 1999 Oct; 38(41):13560-73. PubMed ID: 10521263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of the transthyretin acid denaturation pathways by analytical ultracentrifugation: implications for wild-type, V30M, and L55P amyloid fibril formation.
    Lashuel HA; Lai Z; Kelly JW
    Biochemistry; 1998 Dec; 37(51):17851-64. PubMed ID: 9922152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can self-assemble into amyloid.
    Lai Z; Colón W; Kelly JW
    Biochemistry; 1996 May; 35(20):6470-82. PubMed ID: 8639594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The molecular interaction of 4'-iodo-4'-deoxydoxorubicin with Leu-55Pro transthyretin 'amyloid-like' oligomer leading to disaggregation.
    Sebastião MP; Merlini G; Saraiva MJ; Damas AM
    Biochem J; 2000 Oct; 351(Pt 1):273-9. PubMed ID: 10998371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro.
    Colon W; Kelly JW
    Biochemistry; 1992 Sep; 31(36):8654-60. PubMed ID: 1390650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulating conformational factors in transthyretin amyloid.
    Saraiva MJ; Almeida MR; Alves IL; Bonifácio MJ; Damas AM; Palha JA; Goldsteins G; Lundgren E
    Ciba Found Symp; 1996; 199():47-52; discussion 52-7. PubMed ID: 8915603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An engineered transthyretin monomer that is nonamyloidogenic, unless it is partially denatured.
    Jiang X; Smith CS; Petrassi HM; Hammarström P; White JT; Sacchettini JC; Kelly JW
    Biochemistry; 2001 Sep; 40(38):11442-52. PubMed ID: 11560492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transthyretin quaternary and tertiary structural changes facilitate misassembly into amyloid.
    Kelly JW; Colon W; Lai Z; Lashuel HA; McCulloch J; McCutchen SL; Miroy GJ; Peterson SA
    Adv Protein Chem; 1997; 50():161-81. PubMed ID: 9338081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence for early cytotoxic aggregates in transgenic mice for human transthyretin Leu55Pro.
    Sousa MM; Fernandes R; Palha JA; Taboada A; Vieira P; Saraiva MJ
    Am J Pathol; 2002 Nov; 161(5):1935-48. PubMed ID: 12414539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cys-10 mixed disulfide modifications exacerbate transthyretin familial variant amyloidogenicity: a likely explanation for variable clinical expression of amyloidosis and the lack of pathology in C10S/V30M transgenic mice?
    Zhang Q; Kelly JW
    Biochemistry; 2005 Jun; 44(25):9079-85. PubMed ID: 15966731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transthyretin fibrillogenesis entails the assembly of monomers: a molecular model for in vitro assembled transthyretin amyloid-like fibrils.
    Cardoso I; Goldsbury CS; Müller SA; Olivieri V; Wirtz S; Damas AM; Aebi U; Saraiva MJ
    J Mol Biol; 2002 Apr; 317(5):683-95. PubMed ID: 11955017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of Non-amyloidogenic G101S Transthyretin.
    Wakita Y; Sato T; Chosa K; Suico MA; Sasaki R; Kawano S; Hashimoto N; Teranishi Y; Imai Y; Morioka H; Shuto T; Kai H
    Biol Pharm Bull; 2018; 41(4):628-636. PubMed ID: 29607936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transthyretin forms amyloid fibrils at physiological pH with ultrasonication.
    Misumi Y; Ueda M; Fujimori H; Shinriki S; Meng W; Kim J; Saito S; Obayashi K; Uchino M; Ando Y
    Amyloid; 2008 Dec; 15(4):234-9. PubMed ID: 19065294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cys10 mixed disulfides make transthyretin more amyloidogenic under mildly acidic conditions.
    Zhang Q; Kelly JW
    Biochemistry; 2003 Jul; 42(29):8756-61. PubMed ID: 12873136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The crystal structure of amyloidogenic Leu55 --> Pro transthyretin variant reveals a possible pathway for transthyretin polymerization into amyloid fibrils.
    Sebastião MP; Saraiva MJ; Damas AM
    J Biol Chem; 1998 Sep; 273(38):24715-22. PubMed ID: 9733771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 4'-iodo-4'-deoxydoxorubicin and tetracyclines disrupt transthyretin amyloid fibrils in vitro producing noncytotoxic species: screening for TTR fibril disrupters.
    Cardoso I; Merlini G; Saraiva MJ
    FASEB J; 2003 May; 17(8):803-9. PubMed ID: 12724338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chromium(III) ion and thyroxine cooperate to stabilize the transthyretin tetramer and suppress in vitro amyloid fibril formation.
    Sato T; Ando Y; Susuki S; Mikami F; Ikemizu S; Nakamura M; Suhr O; Anraku M; Kai T; Suico MA; Shuto T; Mizuguchi M; Yamagata Y; Kai H
    FEBS Lett; 2006 Jan; 580(2):491-6. PubMed ID: 16386248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 'In vitro' amyloid fibril formation from transthyretin: the influence of ions and the amyloidogenicity of TTR variants.
    Bonifácio MJ; Sakaki Y; Saraiva MJ
    Biochim Biophys Acta; 1996 May; 1316(1):35-42. PubMed ID: 8634341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.